{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:22:37Z","timestamp":1777270957335,"version":"3.51.4"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Infections by drug-resistant bacteria are a significant threat to human health worldwide although many drug-resistant bacteria are sensitive to aminoglycosides (AGs), an older class of antibiotics. AGs have played a significant role in clinical practice in recent years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Publications from 1 January 2013 to 31 December 2023 that described clinical research of AGs were identified by searching the Web of Science Core Collection Database. Visual presentations of different bibliometric networks were prepared using VOSviewer and CiteSpace.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 915 eligible publications and the annual number of publications increased over time. The United States had the most publications and was at the core of the cooperative network. Italy and Belgium had the highest quality publications, and many of the institutions with high yield and high research quality were in Australia. JA Roberts (University of Queensland, Australia) was the most productive author and was the author of many high-quality studies in cooperation with various other researchers. The majority of publications were in journals that focused on antibacterials, chemotherapy, and pharmacokinetics. Analysis of the most highly cited publications, references, and keywords, indicated that this research mainly focused on infections by drug-resistant bacteria, drug administration in vulnerable populations, safety, pharmacokinetics, combination therapy, and new methods of administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>AGs have an increasingly important role in the treatment of infections by multidrug-resistant bacteria. Therapeutic drug monitoring should be performed in vulnerable populations, such as the elderly, children, and infants, to improve efficacy and reduce toxicity. Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A\u202f&amp;gt;\u202fG gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2025.1532231","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:53:34Z","timestamp":1739948014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk"],"prefix":"10.3389","volume":"16","author":[{"given":"Tengxiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Likai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref76","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the therapeutic range","volume":"44","author":"Abdul-Aziz","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.2174\/1381612821666150901110659","article-title":"Dosing guidelines of aminoglycosides in neonates: a balance between physiology and feasibility","volume":"21","author":"Allegaert","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5414\/CP203545","article-title":"Appropriate therapeutic drug monitoring of antibiotics contributed to lower nephrotoxicity","volume":"58","author":"Alqahtani","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.22207\/JPAM.17.1.52","article-title":"Prevalence and antibiotic sensitivity profile of Bacteria in patients with ear infections","volume":"17","author":"Al-Tulaibawi","year":"2023","journal-title":"Pure Appl. Microbiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/antibiotics12020373","article-title":"Therapeutic drug monitoring of amikacin in neutropenic oncology patients","volume":"12","author":"Aquino","year":"2023","journal-title":"Antibiotics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejpb.2021.04.014","article-title":"Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans","volume":"164","author":"Bacle","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/QCO.0000000000000314","article-title":"The management of multidrug-resistant Enterobacteriaceae","volume":"29","author":"Bassetti","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0196-0709(89)90002-1","article-title":"Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels","volume":"10","author":"Beaubien","year":"1989","journal-title":"Am. J. Otolaryngol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nephro.2018.08.004","article-title":"Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen","volume":"15","author":"Ben Romdhane","year":"2019","journal-title":"Nephrol. Ther."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14787210.2020.1759419","article-title":"Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections","volume":"18","author":"Bilinskaya","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and Pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e00993-19","DOI":"10.1128\/aac.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1093\/jac\/dky239","article-title":"Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients","volume":"73","author":"Boisson","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijantimicag.2018.04.016","article-title":"Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients","volume":"52","author":"Bukkems","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e3929","DOI":"10.1093\/cid\/ciaa621","article-title":"Aminoglycosides and Capreomycin in the treatment of multidrug-resistant tuberculosis: individual patient data meta-analysis of 12 030 patients from 25 countries, 2009-2016","volume":"73","author":"Cegielski","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12877-021-02512-3","article-title":"Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis","volume":"21","author":"Chinzowu","year":"2021","journal-title":"BMC Geriatr."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e01282-17","DOI":"10.1128\/aac.01282-17","article-title":"Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia","volume":"61","author":"Cristea","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0029321","DOI":"10.1128\/AAC.00293-21","article-title":"Amikacin combined with Fosfomycin for treatment of neonatal Sepsis in the setting of highly prevalent antimicrobial resistance","volume":"65","author":"Darlow","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11095-013-1197-y","article-title":"A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates","volume":"31","author":"De Cock","year":"2014","journal-title":"Pharm. Res."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10096-022-04429-0","article-title":"A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin-and carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"41","author":"Demirlenk","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.21037\/atm-20-3686","article-title":"Inhaled antibiotics during mechanical ventilation-why it will work","volume":"9","author":"Desgrouas","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5414\/CP203793","article-title":"Covariates of amikacin disposition in a large pediatric oncology cohort","volume":"59","author":"Dewandel","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J. Bus. Res."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"13137","DOI":"10.22038\/ijp.2021.55656.4383","article-title":"Evaluation of gentamicin ototoxicity in newborn infants: a retrospective observational study","volume":"9","author":"Ekmen","year":"2021","journal-title":"Int J Pediatr."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"106728","DOI":"10.1016\/j.rmed.2021.106728","article-title":"Bronchiectasis and inhaled tobramycin: a literature review","volume":"192","author":"Elborn","year":"2022","journal-title":"Respir. Med."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07853890.2022.2129775","article-title":"Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae","volume":"54","author":"El-Mahallawy","year":"2022","journal-title":"Ann. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/ageing\/afu023","article-title":"Aminoglycosides use in patients over 75 years old","volume":"43","author":"Fraisse","year":"2014","journal-title":"Age Ageing"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bcp.12444","article-title":"Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates","volume":"78","author":"Fuchs","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1093\/jac\/dkaa160","article-title":"In vitro activity of ceftolozane\/tazobactam alone and in combination with amikacin against MDR\/XDR Pseudomonas aeruginosa isolates from Greece","volume":"75","author":"Galani","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/archdischild-2015-309069","article-title":"What do I need to know about aminoglycoside antibiotics?","volume":"102","author":"Germovsek","year":"2017","journal-title":"Arch. Dis. Child. Educ. Pract. Ed."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4140\/TCP.n.2020.162","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease","volume":"35","author":"Golia","year":"2020","journal-title":"Sr Care Pharm."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"106913","DOI":"10.1016\/j.ijantimicag.2023.106913","article-title":"Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant gram-negative bacilli in patients with sepsis and septic shock","volume":"62","author":"Guillamet","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clinthera.2023.03.015","article-title":"Population pharmacokinetics and AUC-guided dosing of tobramycin in the treatment of infections caused by glucose-nonfermenting gram-negative Bacteria","volume":"45","author":"Hashiguchi","year":"2023","journal-title":"Clin. Ther."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/CCM.0000000000002695","article-title":"Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia Postcardiac surgeries: a randomized controlled trial","volume":"46","author":"Hassan","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/infdis\/jis766","article-title":"Assessment of antimicrobial combinations for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae","volume":"207","author":"Hirsch","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijantimicag.2016.10.022","article-title":"Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis","volume":"49","author":"Hodiamont","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40262-022-01143-0","article-title":"Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review","volume":"61","author":"Hodiamont","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"106180","DOI":"10.1016\/j.ijantimicag.2020.106180","article-title":"Therapeutic drug monitoring of commonly used anti-infective agents: a nationwide cross-sectional survey of Australian hospital practices","volume":"56","author":"Imani","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/FTD.0000000000000800","article-title":"Impact of therapeutic drug monitoring on once-daily regimen of amikacin in patients with urinary tract infection: a prospective observational study","volume":"42","author":"Jayakumar","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.2174\/1566524023666230801160452","article-title":"Aminoglycosides: single-or multiple-daily dosing? An updated qualitative systematic review of randomized trials on toxicity and efficacy","author":"Karimzadeh","year":"2023","journal-title":"Curr. Mol. Med."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/FTD.0000000000000904","article-title":"Theoretical performance of nonlinear mixed-effect models incorporating saliva as an alternative sampling matrix for therapeutic drug monitoring in pediatrics: a simulation study","volume":"43","author":"Kruizinga","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1128\/AAC.01309-07","article-title":"Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii","volume":"52","author":"Lim","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/FTD.0000000000000568","article-title":"Impact of disease on amikacin pharmacokinetics and dosing in children","volume":"41","author":"Liu","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2317915","DOI":"10.1080\/22221751.2024.2317915","article-title":"ESKAPE in China: epidemiology and characteristics of antibiotic resistance","volume":"13","author":"Luo","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"115956","DOI":"10.1016\/j.diagmicrobio.2023.115956","article-title":"Drug resistance and susceptibility of amikacin in children with extended-spectrum beta-lactamase-producing Enterobacterales: a systematic review with meta-analysis","volume":"106","author":"Luo","year":"2023","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7727\/wimj.2015.603","article-title":"Gentamicin therapeutic drug monitoring: importance in the hospital setting","volume":"66","author":"Mason","year":"2017","journal-title":"West Ind. Med. J."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000941","article-title":"Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent hemodialysis: a critical review","volume":"44","author":"Matusik","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","article-title":"Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care","volume":"176","author":"McDermott","year":"2022","journal-title":"JAMA Pediatr."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/cpt.2309","article-title":"Clinical Pharmacogenetics implementation consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype","volume":"111","author":"McDermott","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"106219","DOI":"10.1016\/j.ejps.2022.106219","article-title":"Amikacin pharmacokinetics in elderly patients with severe infections","volume":"175","author":"Medell\u00edn-Garibay","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.22207\/JPAM.17.4.43","article-title":"Antimicrobial susceptibility of Klebsiella pneumoniae isolated from intensive and non-intensive care units patients: a one-year retrospective study in a tertiary healthcare hospital, Saudi Arabia","volume":"17","author":"Moustafa","year":"2023","journal-title":"J. Pure Appl. Microbiol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1304011","DOI":"10.3389\/fmicb.2023.1304011","article-title":"Network meta-analysis of antibiotic resistance patterns in gram-negative bacterial infections: a comparative study of carbapenems, fluoroquinolones, and aminoglycosides","volume":"14","author":"Muteeb","year":"2023","journal-title":"Front. Microbiol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fncel.2017.00325","article-title":"Towards the prevention of aminoglycoside-related hearing loss","volume":"11","author":"O'Sullivan","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/thx.2009.131532","article-title":"Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis","volume":"65","author":"Prayle","year":"2010","journal-title":"Thorax"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ng0793-289","article-title":"Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness","volume":"4","author":"Prezant","year":"1993","journal-title":"Nat. Genet."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1128\/AAC.00965-08","article-title":"Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation","volume":"53","author":"Qian","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ph16101353","article-title":"Aminoglycosides-related ototoxicity: mechanisms, risk factors, and prevention in pediatric patients","volume":"16","author":"Rivetti","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13613-021-00834-4","article-title":"An international survey on aminoglycoside practices in critically ill patients: the AMINO III study","volume":"11","author":"Roger","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1128\/AAC.00828-16","article-title":"Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy","volume":"60","author":"Roger","year":"2016","journal-title":"ASM J. CD"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/idr.S150839","article-title":"High-dose amikacin for achieving serum target levels in critically ill elderly patients","volume":"11","author":"Sadeghi","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1039\/D3MA00632H","article-title":"Current advancement in nanomaterial-based emerging techniques for the determination of aminoglycosides antibiotics for antibiotic resistance surveillances","volume":"5","author":"Sajwan","year":"2024","journal-title":"Mater Adv."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1111\/bcp.15823","article-title":"Therapeutic drug monitoring of amikacin in preterm and term neonates with late-onset sepsis. Can saliva samples replace plasma samples?","volume":"89","author":"Samb","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, Polymyxin B, and Tigecycline for clearance of Carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/phar.2203","article-title":"Plazomicin: a next-generation aminoglycoside","volume":"39","author":"Shaeer","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics","volume":"12","author":"Shi","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/jac\/dkaa312","article-title":"Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function","volume":"75","author":"Smit","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/AAC.01157-15","article-title":"Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice","volume":"59","author":"Smits","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17425255.2017.1234606","article-title":"The amikacin research program: a stepwise approach to validate dosing regimens in neonates","volume":"13","author":"Smits","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cmi.2015.12.016","article-title":"Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines","volume":"22","author":"Sol\u00e9-Lleonart","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/ALN.0000000000001570","article-title":"Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis","volume":"126","author":"Sol\u00e9-Lleonart","year":"2017","journal-title":"Anesthesiology"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.juro.2018.10.004","article-title":"Intravesical gentamicin treatment for recurrent urinary tract infections caused by multidrug resistant Bacteria","volume":"201","author":"Stalenhoef","year":"2019","journal-title":"J. Urol."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/antibiotics11010101","article-title":"Effect of different piperacillin-Tazobactam dosage regimens on synergy of the combination with tobramycin against Pseudomonas aeruginosa for the pharmacokinetics of critically ill patients in a dynamic infection model","volume":"11","author":"Tait","year":"2022","journal-title":"Antibiotics"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12913-023-10404-y","article-title":"A qualitative study of the factors impacting implementation of the national action plan to contain antimicrobial resistance (2016-2020) in medical institutions","volume":"24","author":"Tao","year":"2024","journal-title":"BMC Health Serv. Res."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/antibiotics12050860","article-title":"Aminoglycosides for the treatment of severe infection due to resistant gram-negative pathogens","volume":"12","author":"Thy","year":"2023","journal-title":"Antibiotics"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/jpc.15899","article-title":"Randomised controlled trial of nebulised gentamicin in children with bronchiectasis","volume":"58","author":"Twiss","year":"2022","journal-title":"J. Paediatr. Child Health"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/jac\/dkv052","article-title":"Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates","volume":"70","author":"Valitalo","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"24883","DOI":"10.1097\/md.0000000000024883","article-title":"Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1128\/AAC.04379-14","article-title":"Novel approach to optimize synergistic Carbapenem-aminoglycoside combinations against Carbapenem-resistant Acinetobacter baumannii","volume":"59","author":"Yadav","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","article-title":"A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity","volume":"27","author":"Yamada","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ofid\/ofac429","article-title":"Efficacy and safety of Plazomicin in the treatment of Enterobacterales infections: a meta-analysis of randomized controlled trials","volume":"9","author":"Yan","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"977372","DOI":"10.3389\/fphar.2022.977372","article-title":"Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK","volume":"13","author":"Zazo","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1532231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:53:38Z","timestamp":1739948018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1532231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":99,"alternative-id":["10.3389\/fmicb.2025.1532231"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1532231","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"article-number":"1532231"}}